Shanhe Pharmaceutical Excipients released its 2026 half-year report. First-half operating revenue was 522 million yuan, up 10.8% year on year. Net profit attributable to the parent was 96.19 million yuan, up 3.4% year on year. Net profit attributable to the parent after deducting non-recurring items was 86.71 million yuan, up 2.3% year on year. Net operating cash flow was 91.01 million yuan, up 13.4% year on year. Second-quarter operating revenue was 260 million yuan, up 16.7% year on year. Net profit attributable to the parent was 49.13 million yuan, up 7.1% year on year. As of the end of the second quarter, total assets were 1.788 billion yuan, up 4.4% from the end of the previous year. Net assets attributable to the parent were 1.035 billion yuan, up 2.8% from the end of the previous year. The company said its business operations had not changed significantly, and it continued to focus on the research, production and sales of pharmaceutical excipients, while advancing the construction of a high-end excipients intelligent manufacturing base project.
Anhui Sunhere Pharmaceutical Excipients Co LtdFirst-half net profit up 3.4% and revenue up 10.8% year on year.
